Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by scarlet1967on Apr 17, 2021 12:56pm
96 Views
Post# 33017296

RE:RE:RE:RE:RE:RE:RE:RE:RE:Information Circular posted

RE:RE:RE:RE:RE:RE:RE:RE:RE:Information Circular posted Anyone’s compensation should be based on their ongoing performance, the idea of bonuses is to create incentives to deliver results based on objective judgement and not an automatic exercise.  Molson has business background but that is in a different industry, at first many speculated his business ties could be an asset but unfortunately that turn out to be only wishful thinking. Although a good track record is a good start there is no guarantee that would translate to future achievements, in fact past performance only is not indicative of future results regardless whether one has been successful in the same field or not. The reason is future is unpredictable, turbulent and volatile meaning despite having experience and good past execution one is as good as what they are achieving now and going forward, their ability to keep learning and adapting is the key imo. Since the company is public it should be in their daily agenda to support a fair valuation which seems to be the neglected issue. One has to wonder how effectively that issue has been addressed by the company. To simply saying a biotech company is high risk high reward investment is common knowledge and doesn’t add any more clarification/justification  to the investment thesis instead there should be reasonable arguments. In the absence of any decent coverage from analysts it is the company’s duty to produce the reports and discuss them with investment communities retail or institutions. As an investor my question is what has been done to support the valuation and what could/should have been done?

Lee430 wrote: Palinc,
Initialy I was impressed that Molson was joining the BOD, now that the honeymoon is over I am not really sure what need he is filling, can someone speculate as to why he was added to the BOD and how such an expense was justified? 

palinc2000 wrote: The BOD in gneral is not impressive,,,,Most would fit well on the board of a retirement living community,,,,,,I know this is harsh but I think some younger still active and imaginative and demanding  board members would help create a better image,,,,I cant see how Levesque can have a good fit with the current members ...Arena is probably the only one picked by Levesque.

slso what does Molson bring to the table,,,,? Access to Montreal Canadians game!!! 




<< Previous
Bullboard Posts
Next >>